Neonatal Respiratory Distress Syndrome Market is driven by high prevalence of respiratory disorders

Neonatal respiratory distress syndrome, also referred to as infant respiratory distress syndrome is characterized by a particular condition often observed in premature babies, usually born about six weeks before their due dates. During this condition, lungs of the premature infants lose the ability to produce enough surfactants in order to provide oxygen to the body. Surfactants are liquids made up of fat and proteins and it helps the lungs to remain inflated so that infants can breathe in and out immediately after their birth. Hence, the prime cause for the prevalence of neonatal respiratory distress syndrome is the lack of surfactant in the lungs. Various signs and symptoms associated with neonatal respiratory distress syndrome are as follows:

Read Report Overview: https://www.transparencymarketresearch.com/neonatal-respiratory-distress-syndrome.html

Grunting respiration
Flaring nostrils
Cyanosis
Blue-colored lips, fingers and toes
Sharp pulling in the chest
Rapid breathing

Based on the treatments and mediations, the neonatal respiratory distress syndrome market can be segmented as follows:

Surfactant Replacement Therapy: The infants who suffer from respiratory distress syndrome are given surfactant through a breathing tube. Surfactants are administered until the lungs start to make the substance on their own.

Oxygen Therapy: Infants with severe breathing problems are given oxygen therapy through a ventilator or NCPAP machine, i.e., nasal continuous positive airway pressure. This therapy ensures that there is a sufficient supply of oxygen to the infant in order to breathe effectively.

Supportive Therapy: Supportive therapy helps the premature infants to meet their basic needs of nutrition and protection. For instance, use of incubator to keep the baby warm, and fluids and nutrients intake through needles inserted into the needle’s veins.

Other treatments: Other treatments include drugs and therapeutics to cure neonatal respiratory distress syndrome. Example, surfaxin (lucinactant), which was approved in March, 2012 by the U.S. Food and Drug Administration for the treatment of infant respiratory distress syndrome.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2971

Based on geography, the neonatal respiratory distress market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America dominates the neonatal respiratory distress market followed by Europe. The prime reasons which have driven the growth of this market in these regions are high prevalence of respiratory disorders in infants and increasing genetic problems with lung development. According to a survey, neonatal respiratory distress syndrome is estimated to affect around 20,000-30,000 infants each year in the United States. Asia Pacific is the most promising market for the growth of neonatal respiratory distress syndrome market as there are many developing regions that are growing at a steady pace. The major factors which will propel the growth of this market in Asia Pacific are high birth rate, increasing awareness related to the complications of respiratory distress syndrome in infants and increasing pregnancy-induced hypertension due to malnutrition. Moreover, increasing incidences of premature labor and high-risk pregnancy in mothers would drive the Asian market towards future growth.

Many pharmaceutical companies and clinical trial institutes are constantly trying to come up with novel therapeutic development for the treatment of neonatal respiratory distress syndrome. Some of the leading players operating in the neonatal respiratory distress market are Chiesi Farmaceutici SpA, Discovery Laboratories, Inc., Takeda Pharmaceutical Company Limited, Auckland City Hospital, Menzies Research Institute and many others.

Purchase Neonatal Respiratory Distress Syndrome Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=2971

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.